background image for GxP Lifeline
GxP Lifeline
  • 2021-bl-lean-documents_132x132

    Principles of Lean Documentation

    Controlled documents tend to be weighed down with unnecessary information. When lean principles are applied to documentation practices, it becomes evident that most documents can be trimmed down to a comprehensive and useful level while maintaining compliance.

    Full story
  • 2021-bl-effective-failure-investigation_132x132

    Is Your CAPA Process Providing Adequate Return on Investment? If Not, Why Not?

    The FDA has increased focus on the effectiveness of failure investigations during inspections in recent years. A review of 483 observations and warning letters clearly demonstrate the agency’s current concern about the adequacy of failure investigations to truly identify root cause.

    Full story
  • 2021-bl-investigational-device_132x132

    FDA’s IDE: Data-Centric Approach to Med Device Innovation

    An Investigational Device Exemption (IDE) is a regulatory option that allows an investigational medical device to be used in a clinical study in order to collect safety and effectiveness data. This article explains why medical device manufacturers would seek an IDE and how they apply for the designation.

    Full story
  • 2020-bl-5-ways-2020-changed_132x132

    5 Ways 2020 Changed the Regulated Medical Industry

    With 2020 behind us, let’s take stock of what happened during the year and how the face of regulated medical industry has changed. Heading into 2021, be ready for remote options, deferred enforcement of regulations and more.

    Full story
  • 2020-bl-six-steps-qualifying-suppliers_132x132

    Five Best Practices for Ensuring Supplier Quality

    Managing various suppliers is complicated. Lapses in process or product quality along the supply chain can have a negative impact on the end product. This article includes five best practices for establishing more effective oversight of suppliers throughout the supply chain.

    Full story
  • 2020-bl-qarad-brexit_132x132

    Brexit and the Impact on the IVD and MD Industries

    On January 1, 2021 the United Kington will leave the European Union. The implications of this move have a significant impact on manufacturers.

    Full story
  • 2020-bl-managing-compliance-costs_132x132

    EU’s MDR Calls for Summary of Safety and Clinical Performance

    With the fast-approaching Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), medical device manufacturers will be seeing more documentation requirements. One of the new documents is a summary of safety and clinical performance (SSCP). This is one of the annual reports manufacturers must provide throughout the life cycle of a device in order to remain compliant to sell products in the EU.

    Full story
  • 2019-bl-thumb-how-the-tga-regulates-drugs-and-devices

    Australia Offers Wave of Potential for Pharma, Medical Device Manufacturers

    Gathering momentum and power like a monster wave, Australia's life sciences sector is increasingly becoming a beacon for pharmaceutical and medical device manufacturers seeking regulatory approval for their products.

    Full story
  • 2020-bl-thumb-design-control-process_132x132

    What Verification and Validation Activities are Required for a First in Human Study?

    Manufacturers preparing for a first in human (FIH) study of a new medical device face questions. Learn answers about what verification and validation activities are required for a FIH study.

    Full story
  • 2020-bl-thumb-qserveeu-mdr-update

    EU's MDR Extended: Where Do Medical Device Manufacturers Stand?

    The much-anticipated one-year delay of the European Union’s Medical Device Regulation (MDR) finally dropped earlier this month. Gert Bos, Executive Director and Partner of the Qserve Group, breaks down what this means for device manufacturers and for their preparations to recertify under the new regulation through a designated Notified Body.

    Full story
  • 2020-bl-thumb-med-device-ebook

    A Data-Centric Approach to Propel the Future of Device Innovation

    Technology and digital transformation are rapidly altering the way medical device manufacturers accelerate production and innovate new products. A new e-book “Mastering Data to Drive Medical Device Innovation to 2030” looks at how the medtech ecosystem is moving toward a more data-centric approach to quality manufacturing. Automated solutions integrated into a digital platform offer device makers the tools to generate real-time intelligence and insights that will lead to greater innovation over the next decade.

    Full story
  • 2020-bl-thumb-manufacturing-tech-trends-accelerate-time-to-market

    3 Trends That Can Improve Manufacturers’ Speed to Market

    Technologies are evolving and maturing, and regulatory bodies are reacting to remove unnecessary roadblocks for device companies while protecting consumer safety. Manufacturing organizations that embrace these opportunities will be better positioned to achieve significant efficiencies in product discovery and development, regulatory compliance and, ultimately, speed to market.

    Full story
  • 2019-bl-thumb-innovation-and-compliance-cochlear

    Innovation and Compliance Harmonize Perfectly at Cochlear

    Cochlear’s cochlear implants are more than just groundbreaking medical devices — they’re a life-redefining means through which people with hearing loss to connect with the world. Learn how the company is bringing innovative products to more people in need by accelerating quality and compliance processes with robust digital solutions.

    Full story
  • 2019-bl-thumb-mdr-and-notified-bodies

    Uncertainty Regarding EU MDR Underscores Importance of Certification Preparation

    Europe’s new regulation for medical devices, the Medical Device Regulation (MDR) takes effect May 26, 2019. Due to confusion regarding the regulation’s requirements and a lack of Notified Bodies to recertify medical devices under the new law, greater clarity is needed. Learn the latest on the developing situation and what med dev companies can do to prepare to recertify their devices.

    Full story
  • 2019-bl-thumb-brandwood-transition-from-mdd-to-mdr

    6 Tips for a Successful Transition to the EU MDR

    Considering the uncertainties surrounding the European Union’s implementation of the Medical Device Regulation (MDR) beginning in May 2020, many device makers are wondering how to proceed toward certification. Despite a lack of official guidance, there are several steps medical device manufacturers can do to prepare themselves to certify and implement Europe’s new regulations.

    Full story
  • 2017-bl-thumb-top-iso-13485

    FDA’s Plan to Replace QSR With ISO 13485: Pros and Cons

    The U.S. Food and Drug Administration (FDA) plans to replace the Quality System Regulation (QSR) with ISO 13485. An announcement of a formal rule change is expected this fall, so GxP Lifeline asked three medical device industry experts and the Advanced Medical Technology Association (AdvaMed) to weigh the pros and cons of the plan.

    Full story
  • 2019-bl-thumb-socra-associations-tie-in

    Bill of Materials Can Help Relieve Pain Points in Device Design Approval

    Nothing can result in more frustrations for a medical device manufacturer than the complexities and headaches that occur during the product design approval process. But by developing a comprehensive bill of materials (BOM) strategy that boosts design control, your organization can avoid pitfalls and increase the turnaround time of deliverables.

    Full story
  • 2019-bl-thumb-asia-pacific-regulatory-changes-to-med-dev

    Top Regulatory Trends Affecting Med Dev in Asia-Pacific Moving into 2019

    Despite a virtual kaleidoscope of continual regulatory fluctuations, 2019 presents some potentially very attractive market expansion opportunities in Asia-Pacific, including China, India, Australia and Japan. Get a comprehensive overview of device markets and their promising potential.

    Full story
  • 2018-bl-thumb-modernizing

    Modernizing the FDA’s 510(k) Review Process: Pros, Cons and the Twilight Zone, Part 3

    This is the last article of a three-part series on the need to modernize the FDA’s 510(k) program. This blog post explains why using the strictest standard as the foundation for your submissions worldwide, even in countries that are relatively lenient, is the right thing to do in terms of both ethics and economics.

    Full story
  • 2018-bl-thumb-modernizing

    Modernizing the FDA's 510(k) Review Process: Pros, Cons and the Twilight Zone, Part 2

    This is Part 2 of a series of three articles on the need to modernize the FDA’s 510(k) clearance process. This blog post discusses the pros and cons of the program in general and the dangerous loophole in the equivalence approach.

    Full story
[ { "key": "fid#1", "value": ["GxP Lifeline Blog"] } ]